Abeona reports second-quarter ZEVASKYN growth, expanded treatment center network

Abeona Therapeutics reported second-quarter 2026 results on August 13, 2026, along with a business update on its gene therapy ZEVASKYN (prademagene zamikeracel). Five patients were treated with ZEVASKYN during the quarter, three more patients completed treatment in the third quarter to date, and 12 total patient treatments have been completed since launch.¹ The company said revenue was not booked for two of those patients because of low manufacturing yield or failure to meet lot release specifications.¹

Abeona also expanded its qualified treatment center (QTC) network. NewYork-Presbyterian/Columbia University Irving Medical Center and Children's Hospital of Philadelphia were added as QTCs during the quarter.¹ CHOP and University of Texas Medical Branch have begun collecting patient biopsies, and CHOP has treated its first ZEVASKYN patient.¹ In the third quarter, Abeona activated Cincinnati Children's as a new QTC, describing it as one of the largest epidermolysis bullosa treatment centers in the U.S.¹

On reimbursement, Abeona secured New Technology Add-On Payment status from CMS for ZEVASKYN, effective October 1, 2026, under the fiscal year 2027 Hospital Inpatient Prospective Payment System Final Rule.¹ The company said this is expected to support hospital adoption and help access for Medicare patients, who make up about 10 percent of RDEB patients.¹

Abeona also presented 5-year follow-up data from the VIITAL Phase 3 study and a 12-year case report from its Phase 1/2a study at medical meetings during the quarter.¹

Financially, net ZEVASKYN revenue for the quarter ended June 30, 2026 rose 31% quarter-over-quarter to $11.4 million, versus $8.7 million in the first quarter of 2026.¹ Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, down from $191.4 million at year-end 2025.¹